Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC)

You'll soon see Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC).

It increases survival in patients with advanced NSCLC.

Think of it as similar to gefitinib (Iressa). These drugs target growth factors that stimulate tumor growth.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote